The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
Researchers revealed the first U.S. case of a pathogen carrying a mutated strain of E. coli resistant to an antibiotic used as a final defense versus superbugs. As a result, there has been heightened concern that a post-antibiotic era will arrive earlier than predicted.
Emerging therapeutic company investment and deal trends
Biopharma, Biotech, Biotech/Biopharma, Biotechnology, Biotechnology Innovation Organization (BIO), Financing, Follow-On Public Offerings (FOPOs_, Initial Public Offering (IPO), Innovation, IPO, IPOs, Issue Archives, June 2016, M&A, M&A, R&D, Series A Preferred Stock, Venture CapitalThe Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.
Projected blockbuster bio products with potential launches in 2016
Atopic Dermatitis, Bladder, Bladder Cancer, Clinical Trials, Immunotherapies, Issue Archives, June 2016, Launches, Multiple Sclerosis, PD-1/PD-L1 inhibitors, PD-L1 Inhibitor, Potential Blockbusters, Product Launches, Prostacyclin Receptor Agonists, Pulmonary Arterial Hypertension, R&D, Relapsing Multiple Sclerosis (RMS)Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread […]
IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.
Massachusetts and California have been well-known as biotech hubs for quite some time. Now New York City is seeing a surge in bio company activity.
Biotech company of the year
Autoimmune Disease, Autoimmune Diseases, Biologics License Application (BLA), Biotech, Biotech/Biopharma, Biotechnology, Blockbusters, Clinical Trials, Collaboration, Collaborations, IMS Health, Issue Archives, June 2016, Launches, Launches, Partnership, Partnerships, Patents, Product Launches, R&DImmunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
The biotechnology arena’s financing total for 2015 reached unprecedented heights for the second straight year, according to EY’s 29th annual Beyond borders report. Biotech companies raised nearly $71 billion in 2015, well ahead of the previous record of $56 billion totaled during 2014.
Pharma brands are still spending furiously on DTC – something like a billion dollars more in 2015 than in 2014, with more growth expected this year – and patients are still demanding and sharing more information about drugs and medical conditions, with or without approval from their doctors.
